Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 40.04% | 558.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 40.04% | 558.06% | |||
| Cost of Revenue | -- | 44.07% | |||
| Gross Profit | 255.57% | 246.52% | |||
| SG&A Expenses | -0.92% | 6.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.17% | 33.29% | |||
| Operating Income | 238.63% | 149.02% | |||
| Income Before Tax | 205.79% | 165.58% | |||
| Income Tax Expenses | -62.01% | 2,947.89% | |||
| Earnings from Continuing Operations | 248.92% | 156.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 248.92% | 156.32% | |||
| EBIT | 238.63% | 149.02% | |||
| EBITDA | 205.90% | 161.68% | |||
| EPS Basic | 248.84% | 156.24% | |||
| Normalized Basic EPS | 205.39% | 165.47% | |||
| EPS Diluted | 248.41% | 156.24% | |||
| Normalized Diluted EPS | 202.44% | 165.47% | |||
| Average Basic Shares Outstanding | 0.04% | 0.13% | |||
| Average Diluted Shares Outstanding | 1.02% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||